Congestive Heart Failure (Heart Failure) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Congestive heart failure (heart failure) report provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects.
Key Targets in the Heart Failure Pipeline Market
The key targets in the heart failure pipeline market are Atrial Natriuretic Peptide Receptor 1, Beta 1 Adrenergic Receptor, Sodium/Glucose Cotransporter 2, Mineralocorticoid Receptor, Beta 2 Adrenergic Receptor, Myosin, and Beta 3 Adrenergic Receptor. Atrial Natriuretic Peptide Receptor 1 has the highest pipeline products.
Heart Failure Pipeline Market, by Targets
For more target insights, download a free report sample
Key MoA in the Heart Failure Pipeline Market
The key MoA in the heart failure pipeline market are Atrial Natriuretic Peptide Receptor 1 Agonist, Sodium/Glucose Cotransporter 2 Inhibitor, Mineralocorticoid Receptor Antagonist, Beta 1 Adrenergic Receptor Antagonist, Beta 2 Adrenergic Receptor Antagonist, Beta 3 Adrenergic Receptor Antagonist, and Myosin Activator. Atrial Natriuretic Peptide Receptor 1 Agonist have the highest number of pipeline products.
Heart Failure Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Heart Failure Pipeline Market
The key RoA in the heart failure pipeline market are oral, intravenous, subcutaneous, parenteral, intracardiac, intracoronary, and intravenous drip. Oral has the highest number of pipeline products.
Heart Failure Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the Heart Failure Pipeline Market
The key molecule types in the heart failure pipeline market are small molecule, cell therapy, gene therapy, synthetic peptide, oligonucleotide, fusion protein, and monoclonal antibody. Small molecule has the highest number of pipeline products in the heart failure pipeline market.
Heart Failure Pipeline Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the Heart Failure Pipeline Market
The key companies in the heart failure pipeline market are AstraZeneca Plc, Bristol-Myers Squibb Co, Bayer AG, Renova Therapeutics Inc, Celixir Ltd, Cytokinetics Inc, Saillant Therapeutics BV, and Sarfez Pharmaceuticals Inc. AstraZeneca Plc has the highest number of pipeline products.
Heart Failure Pipeline Market, by Companies
To know about more companies, download a free report sample
Market report overview
Key targets | Atrial Natriuretic Peptide Receptor 1, Beta 1 Adrenergic Receptor, Sodium/Glucose Cotransporter 2, Mineralocorticoid Receptor, Beta 2 Adrenergic Receptor, Myosin, and Beta 3 Adrenergic Receptor |
Key MoA | Atrial Natriuretic Peptide Receptor 1 Agonist, Sodium/Glucose Cotransporter 2 Inhibitor, Mineralocorticoid Receptor Antagonist, Beta 1 Adrenergic Receptor Antagonist, Beta 2 Adrenergic Receptor Antagonist, Beta 3 Adrenergic Receptor Antagonist, and Myosin Activator |
Key RoA | Oral, Intravenous, Subcutaneous, Parenteral, Intracardiac, Intracoronary, and Intravenous Drip |
Key molecule types | Small Molecule, Cell Therapy, Gene Therapy, Synthetic Peptide, Oligonucleotide, Fusion Protein, and Monoclonal Antibody |
Key companies | AstraZeneca Plc, Bristol-Myers Squibb Co, Bayer AG, Renova Therapeutics Inc, Celixir Ltd, Cytokinetics Inc, Saillant Therapeutics BV, and Sarfez Pharmaceuticals Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Congestive Heart Failure (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Congestive Heart Failure (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Congestive Heart Failure (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Congestive Heart Failure (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Congestive Heart Failure (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Adicet Bio Inc
Adrenomed AG
AgeX Therapeutics Inc
Akebia Therapeutics Inc
Allysta Pharmaceuticals Inc
AnaCardio AB
Anchored Rsk3 Inhibitors LLC
Angion Biomedica Corp
Animatus Biosciences LLC
Antlia Bioscience Inc
APIE Therapeutics Inc
Araim Pharmaceuticals Inc
ARCA biopharma Inc
ARMGO Pharma Inc
Ascendia Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
Athersys Inc
Avery Therapeutics Inc
Bayer AG
Betagenon AB
BioCardia Inc
Biopeutics Co Ltd
BlueRock Therapeutics LLC
Boehringer Ingelheim International GmbH
Boryung Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
C&C BioPharma LLC
Capricor Therapeutics Inc
Cardiac RSK3 Inhibitors LLC
Cardiol Therapeutics Inc
Cardior Pharmaceuticals GmbH
CCRP Therapeutics GmbH
Celixir Ltd
Cell Tech Pharmed Co
Cellvation Inc
Chong Kun Dang Holdings Corp
Chong Kun Dang Pharmaceutical Corp
Corteria Pharmaceuticals SAS
Creative Medical Technology Holdings Inc
CuronBiotech Inc
Cytokinetics Inc
Daiichi Sankyo Co Ltd
DiNAQOR AG
Dynomics Inc
Eli Lilly and Co
Elyson Pharmaceutical Co Ltd
Ethicare GmbH
Evotec SE
Exscien Corp
F. Hoffmann-La Roche Ltd
G3 Pharmaceuticals Inc
GB Sciences Inc
Genome Biologics UG
GlaxoSmithKline Plc
Guangdong East Sunshine Pharmaceutical Co Ltd
Heartseed Inc
Help Therapeutics
Hemostemix Inc
Hunan Jingfeng Pharmaceutical Co Ltd
Huons Co Ltd
Hyloris Pharmaceuticals SA
I-Cordis LLC
iHeart Japan Corp
Imara Inc
Imbria Pharmaceuticals Inc
Immunwork Inc
Innolife Co Ltd
Innopharmax Inc
Inserm Transfert SA
Intra-Cellular Therapies Inc
INVENT Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Japan Tobacco Inc
Johnson & Johnson
Katakura Industries Co Ltd
KBP Biosciences Co Ltd
Larix Bioscience LLC
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
Lexicon Pharmaceuticals Inc
Madeleine Pharmaceuticals Inc
Mesoblast Ltd
Metcela Inc
Mitsubishi Tanabe Pharma Corp
Moderna Inc
NanoCor Therapeutics Inc
NeoProgen Inc
Novartis AG
Novelstar Pharmaceuticals Inc
NovoMedix LLC
Olatec Therapeutics LLC
Organicell Regenerative Medicine Inc
Orig3N Inc
Orion Corp
Orizuru Therapeutics Inc
Otsuka Pharmaceutical Co Ltd
Palatin Technologies Inc
Paradigm Biopharmaceuticals Ltd
Pfizer Inc
Pharchoice Therapeutics Inc
PhaseBio Pharmaceuticals Inc
Phrixus Pharmaceuticals Inc
Poxel SA
Procella Therapeutics AB
Prolifagen LLC
Proveca Ltd
Q BioMed Inc
Qanatpharma GmbH
Quantum Genomics SA
Qurgen Inc
Ramino-Bio Ltd
Recardio Inc
Regeneron Pharmaceuticals Inc
Renova Therapeutics Inc
Ribomic Inc
Rivus Pharmaceuticals Inc
Rnatives Ltd
Rockwell Medical Inc
Saillant Therapeutics BV
Saje Pharma LLC
Saliogen Therapeutics Inc
Salubris Biotherapeutics Inc
Sana Biotechnology Inc
Sanofi
Sarfez Pharmaceuticals Inc
scPharmaceuticals Inc
Senju Pharmaceutical Co Ltd
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Hongyitang Biomedical Technology Co Ltd
Shanghai Life Science & Technology
Shenzhen Salubris Pharmaceuticals Co Ltd
Shin Poong Pharm Co Ltd
Signal Pharma Ltd
Silver Creek Pharmaceuticals Inc
siRNAgen Therapeutics Corp
Sorrento Therapeutics Inc
Stemedica Cell Technologies Inc
Sumocor LLC
Sun Pharma Advanced Research Company Ltd
Suzhou Pharmavan Cancer Research Center Co Ltd
T&R Biofab Co Ltd
Takeda Pharmaceutical Co Ltd
Techfields Pharma Co Ltd
Tenaya Therapeutics Inc
Titan Pharmaceuticals Inc
Toa Eiyo Ltd
Torrent Pharmaceuticals Ltd
TransThera Sciences (Nanjing) Inc
TreeFrog Therapeutics SAS
Trio Medicines Ltd
Triple-Gene LLC
U.S. Stem Cell Inc
Valo Health LLC
Viatris Inc
ViCardia Therapeutics Inc
Viera BioScience Inc
Vifor Pharma Ltd
Viridian Therapeutics Inc
Viscofan BioEngineering
Windtree Therapeutics Inc
Wuhan LL Science and Technology Development Co Ltd
XyloCor Therapeutics Inc
YAP Therapeutics Inc
Zensun (Shanghai) Sci & Tech Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Heart Failure pipeline market?
The key targets in the heart failure pipeline market are Atrial Natriuretic Peptide Receptor 1, Beta 1 Adrenergic Receptor, Sodium/Glucose Cotransporter 2, Mineralocorticoid Receptor, Beta 2 Adrenergic Receptor, Myosin, and Beta 3 Adrenergic Receptor.
-
What are the key MoA in the Heart Failure pipeline market?
The key MoA in the heart failure pipeline market are Atrial Natriuretic Peptide Receptor 1 Agonist, Sodium/Glucose Cotransporter 2 Inhibitor, Mineralocorticoid Receptor Antagonist, Beta 1 Adrenergic Receptor Antagonist, Beta 2 Adrenergic Receptor Antagonist, Beta 3 Adrenergic Receptor Antagonist, and Myosin Activator.
-
What are the key RoA in the Heart Failure pipeline market?
The key RoA in the heart failure pipeline market are oral, intravenous, subcutaneous, parenteral, intracardiac, intracoronary, and intravenous drip.
-
What are the key molecule types in the Heart Failure pipeline market?
The key molecule types in the heart failure pipeline market are small molecule, cell therapy, gene therapy, synthetic peptide, oligonucleotide, fusion protein, and monoclonal antibody.
-
What are the key companies in the Heart Failure pipeline market?
The key companies in the heart failure pipeline market are AstraZeneca Plc, Bristol-Myers Squibb Co, Bayer AG, Renova Therapeutics Inc, Celixir Ltd, Cytokinetics Inc, Saillant Therapeutics BV, and Sarfez Pharmaceuticals Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.